menu search

HOWL / Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?
Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company treating patients with advanced or metastatic solid tumors with its interleukin 2 INDUKINE molecule. Read More
Posted: Nov 3 2023, 10:26
Author Name: InvestorPlace
Views: 022773

HOWL News  

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?

By InvestorPlace
November 3, 2023

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?

Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This more_horizontal

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

By Seeking Alpha
August 25, 2023

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023 more_horizontal

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 10, 2023

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This comp more_horizontal

Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates

By Zacks Investment Research
May 11, 2023

Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.49. This comp more_horizontal

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates

By Zacks Investment Research
March 23, 2023

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. more_horizontal

Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

By GlobeNewsWire
June 6, 2022

Werewolf Therapeutics to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative bi more_horizontal


Search within

Pages Search Results: